Fig. 1 · Structure

Documents & Downloads

LY 2183240

Cat. No. A11960 CAS 874902-19-9

FAAH inhibitor

LY 2183240 acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide, and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 > 100 μM Antagonist activity at human TRPV1 receptor expressed in HEK293 cells assessed as inhibition of capsaicin-induced intracellular Ca2+ elevation incubated for 5 mins prior to capsaicin-stimulation by spectrofluorimetric analysis [PMID: 23474898]
HEK293 EC50 26.9 μM Agonist activity at rat TRPA1 receptor expressed in HEK293 cells assessed as increase in intracellular Ca2+ concentration by spectrofluorimetric analysis [PMID: 23474898]
HEK293 IC50 49.4 μM Antagonist activity at rat TRPA1 receptor expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced intracellular Ca2+ elevation incubated for 5 mins prior to allyl isothiocyanate-stimulation by spectrofluorimetric analysis [PMID: 23474898]

LY 2183240 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of LY 2183240 from 3 published references. In vitro models include hiPSC-derived neurons; U2OS cells.

LY 2183240 In Vitro Studies

In hiPSC-derived neurons, LY 2183240 at 50 μM significantly decreased weighted mean firing rate to 46.7±5.4% relative to baseline, with a reported IC50 of 59.2 μM. In U2OS cells, treatment at 10 μM for 18 h increased γH2AX expression by approximately 45% relative to vehicle. In cultured cortical neurons from C57BL/6 embryos, application at 10 μM increased the number of spontaneous action potentials compared with before application. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Spontaneous neuronal activity in hiPSC-derived neurons

Cell-based study · hiPSC-derived neurons [1]

In hiPSC-derived neurons, LY 2183240 at 50 μM significantly decreased weighted mean firing rate to 46.7±5.4% relative to baseline. The reported IC50 was 59.2 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
weighted mean firing rate (wMFR)IC50 59.2 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Exposure duration
After treatment, spontaneous neuronal activity was measured for 30 minutes
Method
manually pipetting
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: LY 2183240

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Microelectrode array (MEA) recording (S24, S29, S31, S32); Materials and Methods > Analysis MEA recording (S41, S47); Results > Neurotoxicity assays: cell viability vs. neuronal function (S157, S158); Table 1 (T1.h1, T1.r21)

weighted mean firing rate (wMFR): weighted mean firing rate (wMFR); comparator: baseline — Materials and Methods > Analysis MEA recording (S41); Results > Neurotoxicity assays: cell viability vs. neuronal function (S157, S158)

DNA damage marker expression in U2OS cells

Cell-based study · U2OS cells [2]

U2OS cells were treated at 10 μM for 18 h. Expression of the DNA damage marker γH2AX, measured by flow cytometry, increased by approximately 45% relative to vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Expression levels of the DNA damage marker γH2AX, as measured by flow cytometryγH2AX expression approximately 45%[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
18 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: LY 2183240

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Experimental validation of candidates identified by the best-performing support vector machine model based on the cpg-0012 dataset (S51); STAR★Methods > Method details > Measurement of DDR and cell viability in U2OS cells (S117); Figure 6 legend (S139, S141)

Expression levels of the DNA damage marker γH2AX, as measured by flow cytometry: Expression levels of the DNA damage marker γH2AX, as measured by flow cytometry; comparator: vehicle — Results > Experimental validation of candidates identified by the best-performing support vector machine model based on the cpg-0012 dataset (S51)

Spontaneous action potentials in cultured cortical neurons

Cell-based study · cortical neurons from days 12–14 after initiating a primary culture using the cortex of C57BL/6 embryos [3]

Cortical neurons cultured from C57BL/6 embryonic cortex received treatment at 10 μM. The number of spontaneous action potentials increased compared with before application.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of spontaneous action potentials (sAPs)Reported result an increase in the number of spontaneous action potentials (sAPs); paired t tests, ∗p = 0.0227[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Method
application
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: LY 2183240

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > LY-2183240 excites excitatory mouse cortical neurons (S3, S4, S11)

number of spontaneous action potentials (sAPs): number of spontaneous action potentials (sAPs); comparator: before (left) — Results > LY-2183240 excites excitatory mouse cortical neurons (S4, S11)

LY 2183240 In Vivo Studies

Male C57BL/6 mice received LY 2183240 at 1 mg/kg by intraperitoneal injection before placement in the non-preferred CPP compartment. CPP scores showed no significant differences from saline controls, indicating that treatment did not elicit CPP. [3]

Conditioned place preference in mice

Animal study · male C57BL/6 mice; n = 6 [3]

Male C57BL/6 mice received LY 2183240 at 1 mg/kg by intraperitoneal injection before placement in the non-preferred CPP compartment. CPP scores showed no significant differences from saline controls, indicating that treatment did not elicit CPP.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CPP score(s)Reported result no significant differences were observed between the two groups, indicating that CPP induced by LY-2183240 were not elicited[3]

Conditions shared by the study groups

Route
i.p. (Intraperitoneal) injection
Treatment course
just before placing the mice into non-preferred compartment of CPP chamber on days 3, 5, 7 and 9
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
LY 2183240 1 mg/kgsalineno significant differences were observed between the two groups, indicating that CPP induced by LY-2183240 were not elicited[3]
LY 2183240 1 mg/kg
Model: male C57BL/6 mice; n = 6
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: LY 2183240

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > LY-2183240 alters dwelling time in both preference and non-preference place (S85, S86, S93); STAR★Methods > Experimental and model and study participant details > Animals (S103); STAR★Methods > Method details > Conditioned place preference > Conditioning (Days 3–10) (S212)

CPP score(s): CPP score(s); comparator: saline — Results > LY-2183240 alters dwelling time in both preference and non-preference place (S86, S93)

LY 2183240 1 mg/kg · Results > LY-2183240 alters dwelling time in both preference and non-preference place (S86); STAR★Methods > Method details > Conditioned place preference > Conditioning (Days 3–10) (S212)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 874902-19-9
Applications FAAH inhibitor
Formula C17H17N5O
Molecular Weight 307.35
SMILES
CN(C)C(=O)N1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 56 mg/mL (182.2 mM)
Water Insoluble
Ethanol 56 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

LY 2183240 Research References

  1. [1] Kang KR, Kim CY, Kim J, et al. Establishment of Neurotoxicity Assessment Using Microelectrode Array (MEA) with hiPSC-Derived Neurons and Evaluation of New Psychoactive Substances (NPS). Int J Stem Cells (2022). PMID: 35769054 DOI: 10.15283/ijsc21217 Source material
  2. [2] Seo C, Lim H, Piao Z, et al. Predicting DNA damage response using synthetic cell painting profiles and experimental analysis. iScience (2026). PMID: 41797930 DOI: 10.1016/j.isci.2026.115000 Source material
  3. [3] Jeong YY, Yoo JH, Jeong SY, et al. LY-2183240 enhances reward-seeking behavior with inducing neuronal excitation and early apoptosis in mouse. iScience (2024). PMID: 39524361 DOI: 10.1016/j.isci.2024.111069 Source material

Added to your cart

View Cart Checkout
Loading...